{"id":"NCT00508820","sponsor":"Amgen","briefTitle":"An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP","officialTitle":"An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-02-01","primaryCompletion":"2011-01-01","completion":"2011-03-01","firstPosted":"2007-07-30","resultsPosted":"2012-02-13","lastUpdate":"2022-11-14"},"enrollment":407,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Thrombocytopenic Purpura","Thrombocytopenia","Thrombocytopenic Purpura"],"interventions":[{"type":"BIOLOGICAL","name":"Romiplostim","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This protocol will provide open label romiplostim to adult thrombocytopenic subjects. Romiplostim will be administered by subcutaneous injection once per week. Dose adjustment will be based on platelet counts, and will be allowed throughout the duration of the study. Rescue therapies are allowed at any time during the study. Reductions in concurrent ITP therapies may occur at any time when platelet counts are \\> 50,000.","primaryOutcome":{"measure":"Adverse Events","timeFrame":"Duration of Treatment plus 30 days or End of Study (whichever is later). Approximately 205 weeks.","effectByArm":[{"arm":"Romiplostim (AMG 531) Cohort 1","deltaMin":162,"sd":null},{"arm":"Romiplostim (AMG 531) Cohort 2","deltaMin":215,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26066765"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":61,"n":168},"commonTop":["Headache","Arthralgia","Fatigue","Nausea","Nasopharyngitis"]}}